,compound_id,standard_inchi_key,compound_name,synonym,target_id,target_pref_name,gene_names,wildtype_or_mutant,mutation_info,pubmed_id,standard_type,standard_relation,standard_value,standard_units,activity_comment,ep_action_mode,assay_format,assaytype,assay_subtype,inhibitor_type,detection_tech,assay_cell_line,compound_concentration_value,compound_concentration_value_unit,substrate_type,substrate_relation,substrate_value,substrate_units,assay_description,title,journal,doc_type,annotation_comments,pDTC_Value,SMILES,base_rdkit_smiles
78,CHEMBL3262143,ABWJEIIFONCFKT-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,=,28.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,28.0,C1CN(C(CN1)COC2=CN=CC=C2)C3=NC4=C(C=CC=C4S3)F.Cl,Fc1cccc2sc(N3CCNCC3COc3cccnc3)nc12
400,CHEMBL2087450,AEZVYNVHNCDBQX-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,11.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,11.0,C1CCN(CC1)CCCCC(=O)NC2=NNC(=C2)C3=CC=C(C=C3)C(F)(F)F,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccc(C(F)(F)F)cc2)[nH]n1
433,CHEMBL1643880,AFUWQWYPPZFWCO-LBPRGKRZSA-N,PUMOSETRAG,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21146988.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2C9,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN2CCC1[C@H](C2)NC(=O)C3=CNC4=C(C3=O)SC=C4,O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O
663,CHEMBL399045,AKKGFQRBBVGLEB-KRXBUXKQSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,17869105.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2C9,Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,C1CN(CCC1CN2CCC(CC2)C3=CC=C(C=C3)Cl)C(=O)/C=C/C4=CC(=C(C=C4)Cl)Cl,O=C(/C=C/c1ccc(Cl)c(Cl)c1)N1CCC(CN2CCC(c3ccc(Cl)cc3)CC2)CC1
858,CHEMBL68131,AOOSJYIINXVNHV-UHFFFAOYSA-N,SB-204070,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inconclusive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CCCCN1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)N)Cl,CCCCN1CCC(COC(=O)c2cc(Cl)c(N)c3c2OCCO3)CC1
859,CHEMBL68131,AOOSJYIINXVNHV-UHFFFAOYSA-N,SB-204070,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,39810.7,NM,Not Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,4.40000018605658,CCCCN1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)N)Cl,CCCCN1CCC(COC(=O)c2cc(Cl)c(N)c3c2OCCO3)CC1
1203,CHEMBL2086583,AWJOXQPKTMMFHH-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-13.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-13.0,CC1=C(NN=C1NC(=O)CCCCN2CCCN(CC2)C(=O)C)C3=CC=C(C=C3)OC,COc1ccc(-c2[nH]nc(NC(=O)CCCCN3CCCN(C(C)=O)CC3)c2C)cc1
1461,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21467212.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,PUBLICATION,,10.0,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1c2ccccc2CCc2ccccc21
1462,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22931300.0,INHIBITION,,,,Active,,,,,,,,,,,,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.,Chem. Res. Toxicol.,PUBLICATION,,,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1c2ccccc2CCc2ccccc21
1463,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1c2ccccc2CCc2ccccc21
1630,CHEMBL2087443,BGJJEMSVLGIVLI-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-1.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-1.0,COC1=CC=C(C=C1)C2=CC(=NN2)NC(=O)CCCCN3CCCCC3,COc1ccc(-c2cc(NC(=O)CCCCN3CCCCC3)n[nH]2)cc1
1840,CHEMBL66114,BKVIWGRFRKLFIO-UHFFFAOYSA-N,RS-39604,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,COC1=CC(=CC(=C1)COC2=CC(=C(C=C2C(=O)CCC3CCN(CC3)CCNS(=O)(=O)C)Cl)N)OC,COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1
2129,CHEMBL2087452,BRVURYNCYHYNFR-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-15.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-15.0,CC1CCN(CC1)CCCCC(=O)NC2=NNC(=C2)C3=CC=C(C=C3)OC,COc1ccc(-c2cc(NC(=O)CCCCN3CCC(C)CC3)n[nH]2)cc1
2181,CHEMBL96,BTCSSZJGUNDROE-UHFFFAOYSA-N,GAMMA-AMINOBUTYRIC ACID,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C(CC(=O)O)CN,NCCCC(=O)O
2535,CHEMBL2204363,CAVNQHZFZKMWIY-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21486038.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)Cl.Cl,Cc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1
2554,CHEMBL3262156,CBIFADZHFPXCGB-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,,,,Not Determined,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,,COC1=CC=C(C=C1)OC(=O)N2CCNCC2COC3=CN=CC=C3.Cl,COc1ccc(OC(=O)N2CCNCC2COc2cccnc2)cc1
2569,CHEMBL180101,CBQGYUDMJHNJBX-OALUTQOASA-N,ESREBOXETINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,=,31622.78,NM,inconclusive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,4.499999953328896,CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
2570,CHEMBL180101,CBQGYUDMJHNJBX-OALUTQOASA-N,ESREBOXETINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,31622.8,NM,Inconclusive,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,4.499999678657065,CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
2725,CHEMBL73234,CFJMRBQWBDQYMK-UHFFFAOYSA-N,CARBETAPENTANE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CCN(CC)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2,CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1
2956,CHEMBL1082723,CKLPLPZSUQEDRT-WPCRTTGESA-N,NITD609,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20568778.0,IC50,=,5420.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 in human liver microsome by LC-MS/MS analysis,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,J. Med. Chem.,PUBLICATION,,5.266000713461613,C[C@H]1CC2=C([C@]3(N1)C4=C(C=CC(=C4)Cl)NC3=O)NC5=CC(=C(C=C25)F)Cl,C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12
3609,CHEMBL1770373,CZWQBSKNHUVZLI-UHFFFAOYSA-N,PF-3246799,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21195614.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9,"Pyrimido[4,5-d]azepines as potent and selective 5-HT(2C) receptor agonists: Design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,C1CNCCC2=NC(=NC=C21)CC3=CC=CC=C3,c1ccc(Cc2ncc3c(n2)CCNCC3)cc1
3716,CHEMBL3186763,DCAMTBFFNOHDAW-DYTRJAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,25244572.0,INHIBITION,=,7.0,%,,,,,,,,,,,,,,,Inhibition of human CYP2C9 at 10 uM,"Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus.",J. Med. Chem.,PUBLICATION,,7.0,CN1CCN(C(=NC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)NC3=CC=CC=C3)C1)C,CN1CCN(C)C(=Nc2ccc([N+](=O)[O-])cc2C(=O)Nc2ccccc2)C1
3759,CHEMBL74656,DCSUBABJRXZOMT-RBBKRZOGSA-N,REL-CISAPRIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22931300.0,INHIBITION,,,,Active,,,,,,,,,,,,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.,Chem. Res. Toxicol.,PUBLICATION,,,CO[C@@H]1CN(CC[C@@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC
3760,CHEMBL74656,DCSUBABJRXZOMT-RBBKRZOGSA-N,REL-CISAPRIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inconclusive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CO[C@@H]1CN(CC[C@@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC
3761,CHEMBL74656,DCSUBABJRXZOMT-RBBKRZOGSA-N,REL-CISAPRIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,3162.3,NM,Not Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,5.499996931948306,CO[C@@H]1CN(CC[C@@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC
3762,CHEMBL74656,DCSUBABJRXZOMT-RBBKRZOGSA-N,REL-CISAPRIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,T1/2,>,1.0,HR,,,,,,,,,,,,,,,Half life in human liver microsomes assessed as CYP2C9-mediated parent compound depletion at 1 uM,,ACS Med. Chem. Lett.,PUBLICATION,,1.0,CO[C@@H]1CN(CC[C@@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC
3866,CHEMBL1083788,DFBQTBNRGSIKHN-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,-10.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,-10.0,C1CCN(CC1)CCCCNC(=O)NC2=CN=C(C=C2)C3=CN=C(C=C3)F,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccc(F)nc2)nc1
3979,CHEMBL773,DHMQDGOQFOQNFH-UHFFFAOYSA-N,GLYCINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22931300.0,INHIBITION,,,,Active,,,,,,,,,,,,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.,Chem. Res. Toxicol.,PUBLICATION,,,C(C(=O)O)N,NCC(=O)O
3980,CHEMBL773,DHMQDGOQFOQNFH-UHFFFAOYSA-N,GLYCINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C(C(=O)O)N,NCC(=O)O
3981,CHEMBL773,DHMQDGOQFOQNFH-UHFFFAOYSA-N,GLYCINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)N,NCC(=O)O
3982,CHEMBL773,DHMQDGOQFOQNFH-UHFFFAOYSA-N,GLYCINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)N,NCC(=O)O
4359,CHEMBL3262129,DQNDQNJPABVUOS-BTQNPOSSSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,,,,Not Determined,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,,C1CN([C@H](CN1)COC2=CN=CC=C2)C3=NC4=C(O3)C=CC(=C4)Br.Cl,Brc1ccc2oc(N3CCNC[C@@H]3COc3cccnc3)nc2c1
4415,CHEMBL3262171,DSBWLGAVGSZBLW-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,=,21.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,21.0,CC1=C(C=CC(=C1)NC(=O)N2CCNCC2COC3=CN=CC=C3)Br.Cl,Cc1cc(NC(=O)N2CCNCC2COc2cccnc2)ccc1Br
4591,CHEMBL2087449,DWJPLBZSCNLIAR-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-10.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-10.0,C1CCN(CC1)CCCCC(=O)NC2=NNC(=C2)C3=CC=NC=C3,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccncc2)[nH]n1
4608,CHEMBL1651208,DWTYHCYVKJONSP-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23009245.0,IC50,=,8200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 in human liver microsomes,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,5.086186147616283,C1CCC(C1)N2CC3=C(C2=O)C=CC(=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O,O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)ccc1Cl
4609,CHEMBL1651208,DWTYHCYVKJONSP-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23009245.0,INHIBITION,=,92.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,92.0,C1CCC(C1)N2CC3=C(C2=O)C=CC(=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O,O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)ccc1Cl
4718,CHEMBL11608,DZGWFCGJZKJUFP-UHFFFAOYSA-N,TYRAMINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C1=CC(=CC=C1CCN)O,NCCc1ccc(O)cc1
4904,CHEMBL1643883,FDKJLUOOFWBTDY-HNNXBMFYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21146988.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2C9,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1C2=CC=CC3=C2C(=N1)CN(C3=O)[C@H]4CN5CCC4CC5,Cn1nc2c3c(cccc31)C(=O)N([C@H]1CN3CCC1CC3)C2
4959,CHEMBL46,FELGMEQIXOGIFQ-UHFFFAOYSA-N,ONDANSETRON,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
4960,CHEMBL46,FELGMEQIXOGIFQ-UHFFFAOYSA-N,ONDANSETRON,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
4977,CHEMBL28992,FEROPKNOYKURCJ-CYBMUJFWSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,=,12589.25,NM,Active,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,4.900000142057633,COC1=CC(=C(C=C1C(=O)N[C@@H]2CN3CCC2CC3)Cl)N,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CN2CCC1CC2
4978,CHEMBL28992,FEROPKNOYKURCJ-CYBMUJFWSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,12589.3,NM,Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,4.899998417198648,COC1=CC(=C(C=C1C(=O)N[C@@H]2CN3CCC2CC3)Cl)N,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CN2CCC1CC2
5002,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21467212.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,PUBLICATION,,10.0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
5003,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22931300.0,INHIBITION,,,,Active,,,,,,,,,,,,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.,Chem. Res. Toxicol.,PUBLICATION,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
5004,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
5005,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
5006,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
5023,CHEMBL287045,FFNWMBDISAYHDC-UHFFFAOYSA-N,SDZ-205557,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inconclusive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CCN(CC)CCOC(=O)C1=CC(=C(C=C1OC)N)Cl,CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC
5024,CHEMBL287045,FFNWMBDISAYHDC-UHFFFAOYSA-N,SDZ-205557,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,39810.7,NM,Not Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,4.40000018605658,CCN(CC)CCOC(=O)C1=CC(=C(C=C1OC)N)Cl,CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC
5393,CHEMBL22778,FNKBVTBXFLSTPB-LBPRGKRZSA-N,UH-301,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CCCN(CCC)[C@H]1CCC2=C(C=CC(=C2C1)O)F,CCCN(CCC)[C@H]1CCc2c(F)ccc(O)c2C1
5535,CHEMBL2024087,FQIJPHXWIONJLF-JKOKRWQUSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22171543.0,INHIBITION,<=,25.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 up to 10 uM,Chemistry and behavioral studies identify chiral cyclopropanes as selective a4ß2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.,J. Med. Chem.,PUBLICATION,,25.0,C1CN[C@@H]1COC2=CN=CC(=C2)[C@H]3C[C@@H]3CCO,OCC[C@H]1C[C@@H]1c1cncc(OC[C@@H]2CCN2)c1
5704,CHEMBL1084631,FTPAKCBSUUBRFU-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,-16.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,-16.0,C1CCN(CC1)CCCCNC(=O)NC2=CC=C(C=C2)C3=CC=C(C=C3)F,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccc(F)cc2)cc1
5810,CHEMBL1084364,FWCCJDYYJWWQOS-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,-4.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,-4.0,C1CCN(CC1)CCCCNC(=O)NC2=CN=C(C=C2)C3=CC=CC=C3,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccc2)nc1
6229,CHEMBL3262172,GGWDKUQZZHJDPZ-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,=,7.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,7.0,C1CN(C(CN1)COC2=CN=CC=C2)C(=O)NC3=C(C=C(C=C3)Br)F.Cl,O=C(Nc1ccc(Br)cc1F)N1CCNCC1COc1cccnc1
6634,CHEMBL2087446,GQCWFDPOTSZPCD-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-9.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-9.0,CC1=C(NN=C1NC(=O)CCCCN2CCCCC2)C3=CC=C(C=C3)OC,COc1ccc(-c2[nH]nc(NC(=O)CCCCN3CCCCC3)c2C)cc1
7013,CHEMBL3262162,GYVJDAOHVCIKJN-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,=,14.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,14.0,COC1=CC=C(C=C1)NC(=O)N2CCNCC2COC3=CN=CC=C3.Cl,COc1ccc(NC(=O)N2CCNCC2COc2cccnc2)cc1
7080,CHEMBL1945843,HBDLBTSITBUDIR-GOSISDBHSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22107017.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9,"Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H3 receptor antagonists with potent cognition enhancing activity.",J. Med. Chem.,PUBLICATION,,4.522878745280337,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=CC(=O)N(N=C3)C4=CC=CC=N4,C[C@@H]1CCCN1CCCOc1ccc(-c2cnn(-c3ccccn3)c(=O)c2)cc1
7134,CHEMBL1084365,HCBWAWNFHVHMOV-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,6.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,6.0,COC1=CC=CC=C1C2=NC=C(C=C2)NC(=O)NCCCCN3CCCCC3,COc1ccccc1-c1ccc(NC(=O)NCCCCN2CCCCC2)cn1
7170,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
7171,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
7172,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
7338,CHEMBL2024089,HGSHFGWWOPXUPH-WHOFXGATSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22171543.0,INHIBITION,<=,25.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 up to 10 uM,Chemistry and behavioral studies identify chiral cyclopropanes as selective a4ß2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.,J. Med. Chem.,PUBLICATION,,25.0,CNC(=O)OCC[C@H]1C[C@@H]1C2=CC(=CN=C2)OC[C@@H]3CCN3,CNC(=O)OCC[C@H]1C[C@@H]1c1cncc(OC[C@@H]2CCN2)c1
7383,CHEMBL2204357,HHVBUSGGPUQAOP-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21486038.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,CC1=C(C(=CC=C1)SC2=CC=CC=C2N3CCNCC3)C.Cl,Cc1cccc(Sc2ccccc2N2CCNCC2)c1C
7689,CHEMBL288591,HOMWNUXPSJQSSU-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CN1CCN(CC1)C2=NC3=CC=CC=C3C=C2,CN1CCN(c2ccc3ccccc3n2)CC1
7889,CHEMBL1086333,HSWHSJUFDDMBTI-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,-2.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,-2.0,COC1=CC=CC=C1C2=CC=C(C=C2)NC(=O)NCCCCN3CCCCC3,COc1ccccc1-c1ccc(NC(=O)NCCCCN2CCCCC2)cc1
7927,CHEMBL1939222,HTSQRRQNKJNSLH-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22191331.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9,ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.,J. Med. Chem.,PUBLICATION,,4.301029995663981,C1=C(C=C(C=C1Cl)Cl)OCC2=CC(=O)NN2,O=c1cc(COc2cc(Cl)cc(Cl)c2)[nH][nH]1
8731,CHEMBL1949930,IKXSPLZKOZXPFB-RQBPZYBGSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22226656.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP 2C9,"Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT6 receptor antagonist showing activity in rat social recognition test.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,CC(C)OC1=CC(=CC(=C1)OC)S(=O)(=O)C2=CC3=C(C=C2)[C@@H]4CCNC[C@@H]4O3.Cl,COc1cc(OC(C)C)cc(S(=O)(=O)c2ccc3c(c2)O[C@H]2CNCC[C@@H]32)c1
9424,CHEMBL3261479,IYUQYZMILCFRJI-MRXNPFEDSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,C1CN2CCC1[C@@H](C2)N3CCN4C=CC5=C4C(=CC=C5)C3=O,O=C1c2cccc3ccn(c23)CCN1[C@@H]1CN2CCC1CC2
9553,CHEMBL3261483,JBVRKZZSTULWTO-OAHLLOKOSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,C1CN2CCC1[C@@H](C2)N3CCN4C5=C(C=C(C=C5C3=O)Cl)C=N4,O=C1c2cc(Cl)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
9872,CHEMBL2086585,JJJIVUQWUUXQLP-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,12.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,12.0,CC(=O)N1CCCN(CC1)CCCCC(=O)NC2=NC=C(N2)C3=CC=C(C=C3)OC,COc1ccc(-c2cnc(NC(=O)CCCCN3CCCN(C(C)=O)CC3)[nH]2)cc1
10091,CHEMBL2204360,JOJYHYRCIYAVHN-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21486038.0,IC50,=,39000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,4.4089353929735005,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C.Cl,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1
10279,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21146988.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2C9,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
10280,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
10281,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
10318,CHEMBL2204356,JTQUHGRGBNXQDN-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21486038.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,C1CN(CCN1)C2=CC=CC=C2SC3=C(C(=CC=C3)Cl)Cl.Cl,Clc1cccc(Sc2ccccc2N2CCNCC2)c1Cl
10570,CHEMBL500,JZQKKSLKJUAGIC-UHFFFAOYSA-N,PINDOLOL,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,CC(C)NCC(O)COc1cccc2[nH]ccc12
10571,CHEMBL500,JZQKKSLKJUAGIC-UHFFFAOYSA-N,PINDOLOL,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,CC(C)NCC(O)COc1cccc2[nH]ccc12
10762,CHEMBL2086584,KELGFUJORMNBDM-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,2.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,2.0,CC(CCCN1CCCN(CC1)C(=O)C)C(=O)NC2=NNC(=C2)C3=CC=C(C=C3)OC,COc1ccc(-c2cc(NC(=O)C(C)CCCN3CCCN(C(C)=O)CC3)n[nH]2)cc1
11013,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
11014,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
11246,CHEMBL128,KQKPFRSPSRPDEB-UHFFFAOYSA-N,SUMATRIPTAN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
11247,CHEMBL128,KQKPFRSPSRPDEB-UHFFFAOYSA-N,SUMATRIPTAN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
11467,CHEMBL509540,KUZRWWLVBUPCRK-UHFFFAOYSA-N,A-940894,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,18817367.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Inhibition of CYP2C9 upto 10 uM,"Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.",J. Med. Chem.,PUBLICATION,,,C1CC2=CC=CC=C2C3=C(C1)C(=NC(=N3)N)N4CCNCC4,Nc1nc2c(c(N3CCNCC3)n1)CCCc1ccccc1-2
11492,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21467212.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,PUBLICATION,,10.0,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
11493,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22931300.0,INHIBITION,,,,Not Determined,,,,,,,,,,,,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.,Chem. Res. Toxicol.,PUBLICATION,,,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
11494,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
11495,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
12124,CHEMBL2086582,LKMWIEHGNOUIAH-UHFFFAOYSA-N,WAY-361789,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-8.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-8.0,CC(=O)N1CCCN(CC1)CCCCC(=O)NC2=NNC(=C2)C3=CC=C(C=C3)OC,COc1ccc(-c2cc(NC(=O)CCCCN3CCCN(C(C)=O)CC3)n[nH]2)cc1
12198,CHEMBL1083787,LMGUUVWYFJIKCD-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,-17.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,-17.0,C1CCN(CC1)CCCCNC(=O)NC2=CN=C(C=C2)C3=CC=C(C=C3)F,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccc(F)cc2)nc1
12235,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22328583.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.522878745280337,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
12236,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23033255.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.301029995663981,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
12237,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
12238,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
12239,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
12240,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,31622.8,NM,Not Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,4.499999678657065,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
12281,CHEMBL2087438,LOEWGPWXHKYVIM-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-3.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-3.0,C1CCN(CC1)CCCCC(=O)NC2=NNC(=C2)C3=CC=C(C=C3)Cl,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccc(Cl)cc2)[nH]n1
12776,CHEMBL2087456,LZQMVVGBOPZASC-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-2.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-2.0,COC1=CC=C(C=C1)C2=CC(=NN2)NC(=O)CCCCN3CCCCCC3,COc1ccc(-c2cc(NC(=O)CCCCN3CCCCCC3)n[nH]2)cc1
12867,CHEMBL3261481,MBYAMJFNDALRJQ-OAHLLOKOSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,C1CN2CCC1[C@@H](C2)N3CCN4C5=C(C=CC=C5C3=O)C=N4,O=C1c2cccc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
13038,CHEMBL289469,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,GRANISETRON,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
13039,CHEMBL289469,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,GRANISETRON,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
13148,CHEMBL2087448,MIQNWMJNRQADMN-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-25.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-25.0,C1CCN(CC1)CCCCC(=O)NC2=NNC(=C2)C3=CC=C(C=C3)Br,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccc(Br)cc2)[nH]n1
13324,CHEMBL1084363,MMXFWZCBTFHARB-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,0.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,0.0,C1CCN(CC1)CCCCNC(=O)NC2=CC=C(C=C2)C3=CC=CC=N3,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccn2)cc1
13354,CHEMBL1365455,MNJNPLVXBISNSX-PBWFPOADSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CC(=CC(=C3)Cl)Cl,CN1[C@H]2CC[C@@H]1CC(OC(=O)c1cc(Cl)cc(Cl)c1)C2
13424,CHEMBL33884,MOZPSIXKYJUTKI-UHFFFAOYSA-N,GR-113808,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CN1C=C(C2=CC=CC=C21)C(=O)OCC3CCN(CC3)CCNS(=O)(=O)C,Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc21
13425,CHEMBL33884,MOZPSIXKYJUTKI-UHFFFAOYSA-N,GR-113808,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,10000.0,NM,Not Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,5.0,CN1C=C(C2=CC=CC=C21)C(=O)OCC3CCN(CC3)CCNS(=O)(=O)C,Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc21
13670,CHEMBL2087451,MUFOLRMJGLDINZ-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-33.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-33.0,C1CCN(CC1)CCCCC(=O)NC2=NNC(=C2)C3=CC=CO3,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccco2)[nH]n1
13675,CHEMBL1086332,MUIUUGJVKFYPIF-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,2.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,2.0,C1CCN(CC1)CCCCNC(=O)NC2=CC=C(C=C2)C3=CC=CC=C3,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccc2)cc1
13789,CHEMBL3262144,MXHSBCKYMYQTPI-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,=,26.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,26.0,C1CN(C(CN1)COC2=CN=CC=C2)C3=NC4=C(C=C(C=C4S3)F)F.Cl,Fc1cc(F)c2nc(N3CCNCC3COc3cccnc3)sc2c1
14285,CHEMBL492884,NIJGWJIOMPHDBP-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,18817367.0,ACTIVITY,,,,Not Active,,,,,,,,,,,,,,Inhibition of CYP2C9 upto 10 uM,"Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.",J. Med. Chem.,PUBLICATION,,,CN1CCN(CC1)C2=NC(=NC(=C2)C3=CC=CC=C3)N,CN1CCN(c2cc(-c3ccccc3)nc(N)n2)CC1
14336,CHEMBL42055,NJMYODHXAKYRHW-BLLMUTORSA-N,E-FLUPENTIXOL,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C1CN(CCN1CC/C=C/2\C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CC/C=C2\c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
14479,CHEMBL2024094,NMIIKXFGCKOYRV-WHOFXGATSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22171543.0,INHIBITION,<=,25.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 up to 10 uM,Chemistry and behavioral studies identify chiral cyclopropanes as selective a4ß2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.,J. Med. Chem.,PUBLICATION,,25.0,COCC[C@H]1C[C@@H]1C2=CC(=CN=C2)OC[C@@H]3CCN3,COCC[C@H]1C[C@@H]1c1cncc(OC[C@@H]2CCN2)c1
15319,CHEMBL145725,OGXMGJGFLBSEJW-HNNXBMFYSA-N,RS-16566,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,=,398.11,NM,Active,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,6.399996913372259,CC(C)N1C=NC2=C(C=C(C=C21)Cl)C(=O)N[C@H]3CN4CCC3CC4,CC(C)n1cnc2c(C(=O)N[C@H]3CN4CCC3CC4)cc(Cl)cc21
15320,CHEMBL145725,OGXMGJGFLBSEJW-HNNXBMFYSA-N,RS-16566,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,398.1,NM,Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,6.400007822415902,CC(C)N1C=NC2=C(C=C(C=C21)Cl)C(=O)N[C@H]3CN4CCC3CC4,CC(C)n1cnc2c(C(=O)N[C@H]3CN4CCC3CC4)cc(Cl)cc21
15399,CHEMBL3262125,OIZPYIZBDYGMNM-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,=,20.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,20.0,C1CN(C(CN1)COC2=CN=CC=C2)C3=NC4=CC=CC=C4O3,c1cncc(OCC2CNCCN2c2nc3ccccc3o2)c1
15692,CHEMBL282433,OPNUROKCUBTKLF-UHFFFAOYSA-N,DITOLYLGUANIDINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CC1=CC=CC=C1NC(=NC2=CC=CC=C2C)N,Cc1ccccc1N=C(N)Nc1ccccc1C
16081,CHEMBL1085379,OXIAXPOOKVTTDN-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,-1.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,-1.0,C1CCN(CC1)CCCCNC(=O)NC2=CC=C(C=C2)C3=CC=CC=C3F,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccc2F)cc1
16519,CHEMBL41543,PHNLCHMJDSSPDQ-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N,NC(=O)N1c2ccccc2CCc2ccccc21
16520,CHEMBL41543,PHNLCHMJDSSPDQ-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N,NC(=O)N1c2ccccc2CCc2ccccc21
16679,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
16680,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
16681,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
16771,CHEMBL2087457,PNHTUMMCJLWVTR-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-18.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-18.0,COC1=CC=C(C=C1)C2=CC(=NN2)NC(=O)CCCCN3CCCOCC3,COc1ccc(-c2cc(NC(=O)CCCCN3CCCOCC3)n[nH]2)cc1
16828,CHEMBL2087447,POWHTVORLJYXLJ-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-33.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-33.0,C1CCN(CC1)CCCCC(=O)NC2=NNC(=C2)C3=CC=C(C=C3)F,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccc(F)cc2)[nH]n1
16845,CHEMBL1643881,PPGYKWQFGNLYIY-AWEZNQCLSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21146988.0,IC50,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2C9,Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN2CCC1[C@H](C2)N3CC4=C5C(=NN4)C=CC=C5C3=O,O=C1c2cccc3n[nH]c(c23)CN1[C@H]1CN2CCC1CC2
17100,CHEMBL2392692,PVTFEAGMCGMRRS-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23664879.0,IC50,>,33000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin),"Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.481486060122112,CC1=NC(=NC(=N1)N2CCC(CC2)C(=O)NCC3=C(C=C(C=C3)Br)OC(F)(F)F)NC,CNc1nc(C)nc(N2CCC(C(=O)NCc3ccc(Br)cc3OC(F)(F)F)CC2)n1
17118,CHEMBL3577955,PWDBREUBRYUEGC-BTJKTKAUSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,25893048.0,IC50,>,40000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,CC(C)N1CCN(CC1)C(=O)C2=CC=C(C=C2)CN3CCOCC3.C(=C\C(=O)O)\C(=O)O,CC(C)N1CCN(C(=O)c2ccc(CN3CCOCC3)cc2)CC1
17509,CHEMBL2087455,QENDQZCSFXDDOX-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-15.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-15.0,COC1=CC=C(C=C1)C2=CC(=NN2)NC(=O)CCCCN3CCC(CC3)C(=O)N,COc1ccc(-c2cc(NC(=O)CCCCN3CCC(C(N)=O)CC3)n[nH]2)cc1
17601,CHEMBL565547,QGJVXXSJZAPJME-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,19646865.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9,Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.,Bioorg. Med. Chem. Lett.,PUBLICATION,,10.0,CC1=NN2C(=NC3=C(C2=N1)CCNCC3)CC4=CC=CC=C4,Cc1nc2c3c(nc(Cc4ccccc4)n2n1)CCNCC3
17747,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,=,79.43,NM,Active,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,7.100015437450609,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
17748,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,=,158.49,NM,Active,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,6.799998134593398,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
17749,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,=,501.19,NM,Active,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,6.299997602857746,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
17750,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,79.4,NM,Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,7.100179497572904,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
17751,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,158.5,NM,Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,6.79997073344623,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
17752,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,501.2,NM,Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,6.299988937677887,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
18323,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22931300.0,INHIBITION,,,,Not Determined,,,,,,,,,,,,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.,Chem. Res. Toxicol.,PUBLICATION,,,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
18324,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,=,7943.28,NM,inconclusive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,5.100000128334196,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
18325,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
18326,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
18327,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
18328,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,7943.3,NM,Inconclusive,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,5.0999990348465305,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
18466,CHEMBL39,QZAYGJVTTNCVMB-UHFFFAOYSA-N,SEROTONIN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,=,15848.93,NM,inconclusive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,4.800000052738446,C1=CC2=C(C=C1O)C(=CN2)CCN,NCCc1c[nH]c2ccc(O)cc12
18467,CHEMBL39,QZAYGJVTTNCVMB-UHFFFAOYSA-N,SEROTONIN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C1=CC2=C(C=C1O)C(=CN2)CCN,NCCc1c[nH]c2ccc(O)cc12
18468,CHEMBL39,QZAYGJVTTNCVMB-UHFFFAOYSA-N,SEROTONIN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,15848.9,NM,Inconclusive,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,4.800000874803203,C1=CC2=C(C=C1O)C(=CN2)CCN,NCCc1c[nH]c2ccc(O)cc12
18493,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21467212.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,PUBLICATION,,10.0,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18494,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22931300.0,INHIBITION,,,,Active,,,,,,,,,,,,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.,Chem. Res. Toxicol.,PUBLICATION,,,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18495,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23033255.0,IC50,=,21200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,,Drug Metab. Dispos.,PUBLICATION,,4.673664139071248,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18496,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23297297.0,DRUG METABOLISM,=,0.01,NMOL/MIN,,,,,,,,,,,,,,,Drug metabolism in supersomes expressing human recombinant CYP2C9 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN,,Drug Metab. Dispos.,PUBLICATION,,0.01,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18497,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23297297.0,DRUG METABOLISM,=,0.057,NMOL/MIN,,,,,,,,,,,,,,,Drug metabolism in supersomes expressing human recombinant CYP2C9 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,0.057,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18498,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23297297.0,DRUG METABOLISM,=,0.065,NMOL/MIN,,,,,,,,,,,,,,,Drug metabolism in supersomes expressing human recombinant CYP2C9 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,0.065,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18499,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23297297.0,DRUG METABOLISM,=,0.22,NMOL/MIN,,,,,,,,,,,,,,,Drug metabolism in supersomes expressing human recombinant CYP2C9 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,0.22,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18500,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23297297.0,DRUG METABOLISM,=,0.33,NMOL/MIN,,,,,,,,,,,,,,,Drug metabolism in supersomes expressing human recombinant CYP2C9 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis,,Drug Metab. Dispos.,PUBLICATION,,0.33,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18501,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,=,39810.72,NM,inconclusive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,4.399999967876858,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18502,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18503,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18504,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18505,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,39810.7,NM,Inconclusive,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,4.40000018605658,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
18554,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
18555,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
18556,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
18733,CHEMBL50,REFJWTPEDVJJIY-UHFFFAOYSA-N,QUERCETIN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,14761192.0,KI,=,27000.0,NM,,,,,,,,,,,,,,,Binding affinity towards cytochrome P450 2C9,Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.,J. Med. Chem.,PUBLICATION,,4.568636235841013,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
18734,CHEMBL50,REFJWTPEDVJJIY-UHFFFAOYSA-N,QUERCETIN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22328583.0,IC50,=,10200.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,PUBLICATION,,4.991399828238082,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
18735,CHEMBL50,REFJWTPEDVJJIY-UHFFFAOYSA-N,QUERCETIN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
18736,CHEMBL50,REFJWTPEDVJJIY-UHFFFAOYSA-N,QUERCETIN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,7943.3,NM,Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,5.0999990348465305,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
18737,CHEMBL50,REFJWTPEDVJJIY-UHFFFAOYSA-N,QUERCETIN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,19952.6,NM,Inconclusive,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,4.700000503883016,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
18738,CHEMBL50,REFJWTPEDVJJIY-UHFFFAOYSA-N,QUERCETIN,,P10632,CYTOCHROME P450 2C8,CYP2C8,,,17132069.0,ACTIVITY,=,30.6,%,,,,,,,,,,,,,,,Effect on CYP2C8/CYP2C9 in human liver assessed as tolubutamide methylhydroxylation at 100 uM relative to control,"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.",PLoS Med.,PUBLICATION,,30.6,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
18951,CHEMBL2418364,RIYSYRWQPZAUDK-CAZKFNJPSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23932792.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 in human liver microsomes in presence of NADPH,"Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,C1[C@@H]2CN(C[C@@H]2CN1C3=CC=CC=N3)C(=O)C45CC6CC(C4)CC(C6)C5,O=C(N1C[C@@H]2CN(c3ccccn3)C[C@@H]2C1)C12CC3CC(CC(C3)C1)C2
18979,CHEMBL2204359,RJOWFEDJGNNCDF-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21486038.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,4.468521082957745,C1CN(CCN1)C2=CC=CC=C2SC3=C(C=C(C=C3)Cl)Cl.Cl,Clc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1
19065,CHEMBL83954,RLSGBCUXLRMTPF-UHFFFAOYSA-N,RS-23597-190,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,COC1=CC(=C(C=C1C(=O)OCCCN2CCCCC2)Cl)N,COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1
19204,CHEMBL654,RONZAEMNMFQXRA-UHFFFAOYSA-N,MIRTAZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,=,50.12,NM,Active,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,7.299988937677887,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1CCN2c3ncccc3Cc3ccccc3C2C1
19205,CHEMBL654,RONZAEMNMFQXRA-UHFFFAOYSA-N,MIRTAZAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,50.1,NM,Active,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,7.300162274132754,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1CCN2c3ncccc3Cc3ccccc3C2C1
19239,CHEMBL2087453,RPLWNHKGFXWLSL-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-24.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-24.0,COC1=CC=C(C=C1)C2=CC(=NN2)NC(=O)CCCCN3CCOCC3,COc1ccc(-c2cc(NC(=O)CCCCN3CCOCC3)n[nH]2)cc1
19431,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21467212.0,INHIBITION,<,10.0,%,,,,,,,,,,,,,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,PUBLICATION,,10.0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
19432,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22931300.0,RATIO IC50,=,2.0,,,,,,,,,,,,,,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.,Chem. Res. Toxicol.,PUBLICATION,,2.0,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
19433,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,ACTIVITY,,,,Inhibitor,,,,,,,,,,,,,,"Clinically relevant inhibitors of human liver microsomal P450 enzymes, isoform CYP2C9","Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition",,BOOK,,,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
19434,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,ACTIVITY,,,,Substrate,,,,,,,,,,,,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP2C9","Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition",,BOOK,,,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
19435,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
19436,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
19670,CHEMBL392760,RYBOXBBYCVOYNO-UHFFFAOYSA-N,WAY-181187,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,17948978.0,IC50,>,500000.0,NM,,,,,,,,,,,,,,,Inhibition of human CYP2C9,"Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.",J. Med. Chem.,PUBLICATION,,3.3010299956639813,C1=CC=C2C(=C1)C(=CN2S(=O)(=O)C3=C(N=C4N3C=CS4)Cl)CCN,NCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2ccccc12
19834,CHEMBL31354,SBPRIAGPYFYCRT-UHFFFAOYSA-N,"WAY-100,635",,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4CCCCC4,COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1
20179,CHEMBL8618,SJDOMIRMMUGQQK-UHFFFAOYSA-N,NAN-190,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,COC1=CC=CC=C1N2CCN(CC2)CCCCN3C(=O)C4=CC=CC=C4C3=O,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1
20287,CHEMBL1086577,SLMFOVKWAUVQPC-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,-3.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,-3.0,C1CCN(CC1)CCCCNC(=O)NC2=CN=C(C=C2)C3=CC=CC=N3,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccn2)nc1
20357,CHEMBL3,SNICXCGAKADSCV-JTQLQIEISA-N,NICOTINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC[C@H]1C2=CN=CC=C2,CN1CCC[C@H]1c1cccnc1
20358,CHEMBL3,SNICXCGAKADSCV-JTQLQIEISA-N,NICOTINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC[C@H]1C2=CN=CC=C2,CN1CCC[C@H]1c1cccnc1
21107,CHEMBL2087421,TYDKAHFZLFMNQX-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22369198.0,INHIBITION,=,-19.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 5 uM,From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.,J. Med. Chem.,PUBLICATION,,-19.0,CC1=CC(=CC(=C1S(=O)(=O)N(C)CCOCC(=O)N2CCN(CC2)C3CCN(CC3)C)C)OC,COc1cc(C)c(S(=O)(=O)N(C)CCOCC(=O)N2CCN(C3CCN(C)CC3)CC2)c(C)c1
21118,CHEMBL2205045,TYKBKDLIAKRVRZ-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21486038.0,IC50,=,40000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,4.3979400086720375,CC1=CC=C(C=C1)SC2=CC=CC=C2N3CCNCC3.Cl,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1
21266,CHEMBL498770,UBHYDQAARZKHEZ-UHFFFAOYSA-N,IODOPHENPROPIT,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C1=CC(=CC=C1CCN=C(N)SCCCC2=CN=CN2)I,NC(=NCCc1ccc(I)cc1)SCCCc1cnc[nH]1
21395,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3C2C1
21396,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3C2C1
21672,CHEMBL3262174,ULCUTKYYKKNHQX-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,=,62.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,62.0,C1CN(C(CN1)COC2=CN=CC=C2)C(=O)NC3=CC=C(C=C3)C(=O)C4=CC=CC=C4.Cl,O=C(c1ccccc1)c1ccc(NC(=O)N2CCNCC2COc2cccnc2)cc1
21733,CHEMBL38288,UMTDAKAAYOXIKU-HXUWFJFHSA-N,WAY-100135,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CC(C)(C)NC(=O)[C@H](CN1CCN(CC1)C2=CC=CC=C2OC)C3=CC=CC=C3,COc1ccccc1N1CCN(C[C@@H](C(=O)NC(C)(C)C)c2ccccc2)CC1
21871,CHEMBL1084876,UPVXJFQSDLKQRB-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,-18.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,-18.0,C1CCN(CC1)CCCCNC(=O)NC2=CC=C(C=C2)C3=CN=C(C=C3)F,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccc(F)nc2)cc1
21947,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
21948,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
22038,CHEMBL2087458,UTZCOSNAHHZOGH-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-1.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-1.0,COC1=CC=C(C=C1)C2=CC(=NN2)NC(=O)CCCCN3CCCNCC3,COc1ccc(-c2cc(NC(=O)CCCCN3CCCNCC3)n[nH]2)cc1
22138,CHEMBL3261486,UWHBCOHEASCLEA-CQSZACIVSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,C1CN2CCC1[C@@H](C2)N3CCN4C5=C(C3=O)C=CC=C5NC4=O,O=C1c2cccc3[nH]c(=O)n(c23)CCN1[C@@H]1CN2CCC1CC2
22309,CHEMBL2087444,VAEUZWBERFNXLX-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-10.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-10.0,COC1=CC=CC(=C1)C2=CC(=NN2)NC(=O)CCCCN3CCCCC3,COc1cccc(-c2cc(NC(=O)CCCCN3CCCCC3)n[nH]2)c1
22448,CHEMBL2087459,VDQDOBJGSUGYMM-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-28.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-28.0,COC1=CC=C(C=C1)C2=CC(=NN2)NC(=O)CCCCN3CCC(=O)NCC3,COc1ccc(-c2cc(NC(=O)CCCCN3CCNC(=O)CC3)n[nH]2)cc1
22608,CHEMBL2205054,VHKBDODTXKHVJR-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21486038.0,IC50,=,34000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,4.468521082957745,CC1=C(C=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C.Cl,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1C
23902,CHEMBL828,WJFKNYWRSNBZNX-UHFFFAOYSA-N,PHENOTHIAZINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC3=CC=CC=C3S2,c1ccc2c(c1)Nc1ccccc1S2
23903,CHEMBL828,WJFKNYWRSNBZNX-UHFFFAOYSA-N,PHENOTHIAZINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC3=CC=CC=C3S2,c1ccc2c(c1)Nc1ccccc1S2
23972,CHEMBL3261482,WLINCFBAKQHMPZ-OAHLLOKOSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,C1CN2CCC1[C@@H](C2)N3CCN4C5=C(C=C(C=C5C3=O)F)C=N4,O=C1c2cc(F)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2
24254,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
24255,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
24410,CHEMBL3262135,WVUAJTKMQULXHI-BTQNPOSSSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,=,33.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,33.0,COC1=CC2=C(C=C1)N=C(S2)N3CCNC[C@@H]3COC4=CN=CC=C4.Cl,COc1ccc2nc(N3CCNC[C@@H]3COc3cccnc3)sc2c1
24552,CHEMBL266591,WYWNEDARFVJQSG-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,=,39810.72,NM,inconclusive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,4.399999967876858,CC1=C(C2=C(N1)C=CC(=C2)O)CCN,Cc1[nH]c2ccc(O)cc2c1CCN
24553,CHEMBL266591,WYWNEDARFVJQSG-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,POTENCY,=,39810.7,NM,Inconclusive,,,,,,,,,,,,,,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9. (Class of assay: confirmatory) [Related pubchem assays: 885, 884, 410 ]",PUBCHEM BIOASSAY DATA SET,,DATASET,,4.40000018605658,CC1=C(C2=C(N1)C=CC(=C2)O)CCN,Cc1[nH]c2ccc(O)cc2c1CCN
24571,CHEMBL19215,WZHJKEUHNJHDLS-QTGUNEKASA-N,METERGOLINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21
24572,CHEMBL19215,WZHJKEUHNJHDLS-QTGUNEKASA-N,METERGOLINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21
24739,CHEMBL3261485,XDJFTOOYWJXAAZ-MRXNPFEDSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24755431.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin),The discovery of diazepinone-based 5-HT3 receptor partial agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,COC1=CC2=C3C(=C1)C(=O)N(CCN3N=C2)[C@@H]4CN5CCC4CC5,COc1cc2c3c(cnn3CCN([C@@H]3CN4CCC3CC4)C2=O)c1
25018,CHEMBL2087454,XJQFQLWVHXSRMJ-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-22.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-22.0,COC1=CC=C(C=C1)C2=CC(=NN2)NC(=O)CCCCN3CCNC(=O)C3,COc1ccc(-c2cc(NC(=O)CCCCN3CCNC(=O)C3)n[nH]2)cc1
25351,CHEMBL18772,XRXDAJYKGWNHTQ-UHFFFAOYSA-N,QUIPAZINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C1CN(CCN1)C2=NC3=CC=CC=C3C=C2,c1ccc2nc(N3CCNCC3)ccc2c1
25352,CHEMBL18772,XRXDAJYKGWNHTQ-UHFFFAOYSA-N,QUIPAZINE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inconclusive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,C1CN(CCN1)C2=NC3=CC=CC=C3C=C2,c1ccc2nc(N3CCNCC3)ccc2c1
25457,CHEMBL2205043,XUMDENDMRHWGGR-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21486038.0,IC50,=,31000.0,NM,,,,,,,,,,,,,,,Inhibition of human recombinant CYP2C9 using dibenzylfluorescein after 45 mins by fluorescence spectrophotometric analysis,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,4.508638306165727,C1CN(CCN1)C2=CC=CC=C2SC3=CC=C(C=C3)Cl.Cl,Clc1ccc(Sc2ccccc2N2CCNCC2)cc1
26010,CHEMBL86304,YHXISWVBGDMDLQ-UHFFFAOYSA-N,MOCLOBEMIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1
26011,CHEMBL86304,YHXISWVBGDMDLQ-UHFFFAOYSA-N,MOCLOBEMIDE,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1
26075,CHEMBL2087445,YJOREKPBKODAPH-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,22468936.0,INHIBITION,=,-7.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,"Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789).",J. Med. Chem.,PUBLICATION,,-7.0,COC1=CC=CC=C1C2=CC(=NN2)NC(=O)CCCCN3CCCCC3,COc1ccccc1-c1cc(NC(=O)CCCCN2CCCCC2)n[nH]1
26293,CHEMBL1083485,YOCUJVXRRWEPDN-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,20465311.0,INHIBITION,=,-10.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 3 uM by Gentest method,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,PUBLICATION,,-10.0,C1CCN(CC1)CCCCNC(=O)NC2=CN=C(C=C2)C3=CC=CC=C3F,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccc2F)nc1
26611,CHEMBL1738699,YVPGZQLRPAGKLA-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,21855338.0,INHIBITION,=,81.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 at 10 uM,Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.,Bioorg. Med. Chem. Lett.,PUBLICATION,,81.0,CC1=C(C=CC(=C1)C(=O)N)N2C(=CC=C2C3=CC=C(C=C3)N4C=CN=C4)CCC(=O)O,Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2)cc1
26702,CHEMBL3262168,YXVBKPDMQWCFGZ-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,=,10.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,10.0,COC1=C(C=C(C=C1)NC(=O)N2CCNCC2COC3=CN=CC=C3)Cl.Cl,COc1ccc(NC(=O)N2CCNCC2COc2cccnc2)cc1Cl
27407,CHEMBL56564,ZNRGQMMCGHDTEI-ITGUQSILSA-N,TROPISETRON,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,AC50,,,,inactive,,,,,,,,,,,,,,PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active,PUBCHEM BIOASSAY DATA SET,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CN1[C@H]2CC[C@@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2
27408,CHEMBL56564,ZNRGQMMCGHDTEI-ITGUQSILSA-N,TROPISETRON,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CN1[C@H]2CC[C@@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2
27409,CHEMBL56564,ZNRGQMMCGHDTEI-ITGUQSILSA-N,TROPISETRON,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,KI,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,cell_based,,,,,BTI-TN-5B1-4,,,,,,,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CN1[C@H]2CC[C@@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2
27502,CHEMBL1651219,ZQBPXBADOJMCRU-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23009245.0,IC50,=,4000.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 in human liver microsomes,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,5.3979400086720375,C1CCC(C1)N2C(=O)C3=C(S2)C=C(C=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O,O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl
27503,CHEMBL1651219,ZQBPXBADOJMCRU-UHFFFAOYSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,23009245.0,INHIBITION,=,93.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,93.0,C1CCC(C1)N2C(=O)C3=C(S2)C=C(C=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O,O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl
27728,CHEMBL3262132,ZWCUBSOPHPGVRD-UTONKHPSSA-N,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,24814197.0,INHIBITION,=,22.0,%,,,,,,,,,,,,,,,Inhibition of CYP2C9 (unknown origin) at 10 uM,Discovery of Novel 2-((Pyridin-3-yloxy)methyl)piperazines as a7 Nicotinic Acetylcholine Receptor Modulators for the Treatment of Inflammatory Disorders.,J. Med. Chem.,PUBLICATION,,22.0,C1CN([C@H](CN1)COC2=CN=CC=C2)C3=NC4=C(O3)C=CC=N4.Cl,c1cncc(OC[C@H]2CNCCN2c2nc3ncccc3o2)c1
28259,CHEMBL3823832,,,,P11712,CYTOCHROME P450 2C9,CYP2C9,,,,IC50,=,6900.0,NM,,,,,,,,,,,,,,,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylation by LC-MS/MS analysis,In vivo phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents,MedChemComm,PUBLICATION,,5.161150909262744,CC1=C(C2=CC=CC=C2S1)[C@@H]3C=CNC=N3,Cc1sc2ccccc2c1[C@@H]1C=CNC=N1
